Format

Send to

Choose Destination
World J Surg Oncol. 2016 Aug 11;14(1):212. doi: 10.1186/s12957-016-0969-3.

Gastric biomarkers: a global review.

Author information

1
Department of Pathology and Laboratory Medicine, University of Saskatchewan, 103 Hospital Drive, Saskatoon, SK, S7N 0W8, Canada. nmb509@mail.usask.ca.
2
Department of Surgery, University of Alberta, 116 St & 85 Ave, Edmonton, T6G 2R3, T6G 2B7, AB, Canada.
3
Division of Medical Oncology, University of Saskatchewan, 103 Hospital Drive, Saskatoon, SK, S7N 0W8, Canada.
4
Department of General Surgery, University of Saskatchewan, 103 Hospital Drive, Saskatoon, SK, S7N 0W8, Canada.

Abstract

BACKGROUND:

Gastric cancer is an aggressive disease with a poor 5-year survival and large global burden of disease. The disease is biologically and genetically heterogeneous with a poorly understood carcinogenesis at the molecular level. Despite the many prognostic, predictive, and therapeutic biomarkers investigated to date, gastric cancer continues to be detected at an advanced stage with resultant poor clinical outcomes.

MAIN BODY:

This is a global review of gastric biomarkers with an emphasis on HER2, E-cadherin, fibroblast growth factor receptor, mammalian target of rapamycin, and hepatocyte growth factor receptor as well as sections on microRNAs, long noncoding RNAs, matrix metalloproteinases, PD-L1, TP53, and microsatellite instability.

CONCLUSION:

A deeper understanding of the pathogenesis and biological features of gastric cancer, including the identification and characterization of diagnostic, prognostic, predictive, and therapeutic biomarkers, hopefully will provide improved clinical outcomes.

KEYWORDS:

Biomarkers; Gastric cancer; Therapy

PMID:
27514667
PMCID:
PMC4982433
DOI:
10.1186/s12957-016-0969-3
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center